Evolus (NASDAQ:EOLS) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Evolus (NASDAQ:EOLS) announced its quarterly earnings results on Tuesday. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09), reports. The business had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million.

Here are the key takeaways from Evolus’ conference call:

• Company highlights portfolio momentum — Jeuveau reached ~14% U.S. toxin share and Evolysse has >3,000 purchasing accounts with Evolysse Sculpt expected to file/receive FDA approval in Q4 and a large sampling program planned for Q2 2026.
• Solid 2025 performance and explicit 2026 targets — full‑year 2025 revenue was $297.2M (+12%)$90.3M (+14%)$327M–$337M with an expectation of full‑year profitability (low‑to‑mid single‑digit adjusted EBITDA) and 13%–15% adjusted EBITDA by 2028.
• Improved cost structure and liquidity — management rebased expenses in mid‑2025, expects non‑GAAP OpEx of $210M–$216M in 2026 (0%–3% growth), ended Q4 with $53.8M cash and access to a revolving facility plus additional debt tranches, and says it is not planning an equity raise.
• Ongoing market and policy headwinds — U.S. injectable procedural volumes declined in 2025, the filler market remains pressured, and Evolus products imported from France are currently subject to a 15% tariff (possible further tariff risk and uncertain recovery of prior tariffs), while new competitor toxin launches in 2026 could create near‑term sampling pressure.

Evolus Trading Up 29.8%

EOLS traded up $1.23 on Wednesday, hitting $5.36. 4,751,815 shares of the company’s stock were exchanged, compared to its average volume of 1,194,114. Evolus has a fifty-two week low of $4.09 and a fifty-two week high of $14.60. The stock has a market cap of $347.44 million, a price-to-earnings ratio of -5.83 and a beta of 1.02. The firm has a 50-day moving average price of $5.11 and a 200-day moving average price of $6.24.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Mizuho set a $15.00 target price on Evolus in a research report on Wednesday, February 4th. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright reduced their target price on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider directly owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.10% of the stock is owned by company insiders.

Institutional Trading of Evolus

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. purchased a new stake in shares of Evolus in the fourth quarter valued at approximately $34,000. Wexford Capital LP purchased a new position in Evolus during the third quarter worth approximately $37,000. Aquatic Capital Management LLC acquired a new position in Evolus during the third quarter worth $48,000. State of Wyoming acquired a new position in Evolus during the fourth quarter worth $63,000. Finally, Tower Research Capital LLC TRC grew its holdings in Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after buying an additional 5,691 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Key Evolus News

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $13.00 price target (~122% upside from recent levels), which can attract bullish flows and coverage-driven buying. BTIG Reaffirmation
• Positive Sentiment: Evolus raised FY2026 revenue guidance to $327M–$337M, above the Street (~$316.3M), signaling stronger top-line momentum and supporting upside to estimates. 2026 Revenue Guidance
• Positive Sentiment: Company press release highlights near-$300M 2025 revenue, sixth consecutive year of double-digit growth, and a stated expectation of sustainable profitability beginning in 2026 — a strategic narrative that supports a re-rating if execution continues. BusinessWire Results
• Positive Sentiment: Quarterly revenue of $90.3M came in slightly above analyst estimates (~$89.6M), providing a tangible beat on the top line despite mixed commentary on margins and EPS. Quarterly Results Deck
• Neutral Sentiment: Earnings call transcripts and highlights are available for detail on growth drivers (international expansion, product portfolio) and management’s cadence for profitability; useful for modeling but not an immediate catalyst on their own. Earnings Call Transcript
• Neutral Sentiment: Zacks reported EPS of $0.06 that matched its consensus — this suggests some analysts see the quarter as in-line even as revenue and guidance pushed the stock higher. Zacks EPS Report
• Neutral Sentiment: Reported short-interest data shows anomalies (zeros/NaN), indicating the published short-interest figures are unreliable right now and shouldn’t be treated as a clear supply signal. Short Interest Data
• Negative Sentiment: There are conflicting EPS reports across outlets (some note a miss vs. consensus and others report an in-line beat), creating near-term uncertainty about profitability and margins that could temper multiple expansion until numbers are reconciled. Mixed EPS Reporting

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.